Renalytix (Reg S) (RENX)

Sector:

Health Care

Index:

FTSE AIM All-Share

 0.000p
   
  • Closing Price Chg:
      0.000p
  • 52 Week High: 17.50
  • 52 Week Low: 6.75
  • Currency: UK Pounds
  • Shares Issued: 189.93m
  • Volume: 0
  • RiskGrade: 348
  • Beta: 0.01

RENX Overview

RenalytixAI is a developer of artificial intelligence (AI) enabled clinical decision support solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care and patient stratification for drug clinical trials.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -1293.5% n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 8.0 n/a
Pr/Book n/a  
Latest F'cast
Revenue -32.7% n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

RENX Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-20 n/a (10.61) (16.00)¢ n/a n/a n/a n/a 0.0%
30-Jun-21 1.49 (35.79) (43.00)¢ n/a n/a n/a n/a 0.0%
30-Jun-22 2.97 (49.63) (78.00)¢ n/a n/a n/a n/a 0.0%
30-Jun-23 3.40 (45.60) (55.00)p n/a n/a n/a n/a 0.0%
30-Jun-24 2.29 (33.45) (31.00)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

RENX Company Announcements

Holding(s) in Company 27-Jun-2025 13:09 RNS
Holding(s) in Company 26-Jun-2025 11:48 RNS
kidneyintelX.dkd data presented at ERA Congress 17-Jun-2025 07:00 RNS

RENX ShareCast News

Renalytix enters new collaboration with NYKHM 03-Jun-2025 ShareCast
Renalytix Q3 revenues up 20pc 10-Apr-2025 ShareCast
Renalytix terminates formal sale process 20-Aug-2024 ShareCast

Latest RENX Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

RENX Market Data

Currency UK Pounds
Share Price 7.00p
Closing Price Change 0.000p
% Change 0.00 %
52 Week High 17.50
52 Week Low 6.75
Volume 0
Shares Issued 189.93m
Beta 0.01
RiskGrade 348

RENX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
18.52% above the market average18.52% above the market average18.52% above the market average18.52% above the market average18.52% above the market average
57.58% above the sector average57.58% above the sector average57.58% above the sector average57.58% above the sector average57.58% above the sector average
Price Trend
86.43% below the market average86.43% below the market average86.43% below the market average86.43% below the market average86.43% below the market average
72.22% below the sector average72.22% below the sector average72.22% below the sector average72.22% below the sector average72.22% below the sector average
Income Not Available
Growth
29.41% below the market average29.41% below the market average29.41% below the market average29.41% below the market average29.41% below the market average
37.14% below the sector average37.14% below the sector average37.14% below the sector average37.14% below the sector average37.14% below the sector average

RENX Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

RENX Key Personnel

CEO James Renwick McCullough

Top of Page